Crinetics Pharmaceuticals
Crinetics Pharmaceuticals develops therapies for endocrine diseases and endocrine-related tumors, with a pipeline that includes Paltusotine, Atumelnant, and an Oral PTH Antagonist.
Services
Crinetics Pharmaceuticals develops therapies for endocrine diseases and endocrine-related tumors. They offer expanded access programs designed to provide investigational drugs to patients who do not qualify for clinical trials. In addition, the company engages in partnerships and collaborations to advance medical research and drug development. They also provide educational resources and support for patients with endocrine diseases.
Products
Crinetics Pharmaceuticals has a diverse pipeline of drugs in various stages of development. Key investigational treatments include Paltusotine, a drug aimed at treating acromegaly; Atumelnant, targeting endocrine disorders; and an Oral PTH Antagonist for managing parathyroid hormone levels. These products are currently undergoing clinical trials and are pivotal to the company's mission of addressing unmet medical needs in endocrine therapy.
Clinical Trials
Crinetics Pharmaceuticals conducts extensive clinical trials for its investigational treatments. Notably, they are investigating a once-daily oral treatment for acromegaly, a condition characterized by excessive growth hormone. These clinical trials are critical for ensuring the safety and efficacy of new therapies before they become widely available to patients. The company's clinical research is a cornerstone of its strategy to bring innovative solutions to endocrine disorders.
Collaborations
Crinetics Pharmaceuticals actively engages in partnerships and collaborations to further its research and drug development efforts. These collaborations play a significant role in enhancing the company's capabilities and accelerating the discovery of new treatments. Through strategic partnerships, Crinetics aims to leverage external expertise and resources, thereby advancing the development of cutting-edge therapies for endocrine diseases.